CIP
ABCL icon

Cornerstone Investment Partners’s AbCellera Biologics ABCL Stock Holding History

Cornerstone Investment Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,725
Closed -$180K – 203
2022
Q4 		$180K Sell
17,725
-1,300
-7% -$15K 0.01% 176
2022
Q3 		$188K Hold
19,025
– – 0.01% 156
2022
Q2 		$203K Hold
19,025
– – 0.01% 151
2022
Q1 		$185K Buy
+19,025
New +$180K 0.01% 211

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cornerstone Investment Partners's ABCL Position: Q1 2023 in Review

Cornerstone Investment Partners sold out of AbCellera Biologics (ABCL) in Q1 2023, closing a stake of 17,725 shares — an estimated $180K sold.

Cornerstone Investment Partners first reported a position in ABCL in Q1 2022 and held it in 4 quarters. The position peaked at $203K in Q2 2022. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

  • Cornerstone Investment Partners reported no remaining AbCellera Biologics position as of Q1 2023 after selling out during the quarter.
  • Cornerstone Investment Partners sold 17,725 AbCellera Biologics shares in Q1 2023, an estimated $180K.
  • Cornerstone Investment Partners first reported a position in AbCellera Biologics in Q1 2022 and held it in 4 quarters.
  • Cornerstone Investment Partners's AbCellera Biologics position peaked at $203K in Q2 2022.
  • 183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on Cornerstone Investment Partners's 13F filing for Q1 2023, filed 21 Apr 2023.